Melvin R. Goodes Prize
The Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery honors an innovative researcher who has made a significant and lasting impact in the field.
Drug discovery researchers are often under recognized and make critical contributions toward the development of effective treatments and a cure for Alzheimer's disease. The Goodes Prize recognizes their determined efforts. It is named for Melvin R. Goodes, a distinguished leader in the pharmaceutical industry, who brought about drug breakthroughs that improved millions of lives.
As a leader in supporting the most promising Alzheimer's drug discovery research worldwide, the ADDF is proud to present the Goodes Prize to those men and women who have dedicated their careers to finding a cure for this devastating disease. It includes a grant of $150,000 to support the winner's future research in Alzheimer's drug discovery.
2015: Frank Longo, MD, PhD
2016: D. Martin Watterson, PhD
2018: Michela Gallagher, PhD
2019: Jeffrey Cummings, MD
Nomination and Selection Process
The Selection Committee includes leaders in Alzheimer’s research and drug discovery. The Committee nominates a select group for consideration. Top nominees are asked to submit a proposal that includes a biography, summary of past work, and a description of innovative research in need of funding. The Selection Committee chooses the winner from this pool of nominees. (Individuals on the Selection Committee are not eligible to receive the award.)
To be eligible, nominees must:
- Be a professionally active (i.e., not retired) investigator with an interdisciplinary research career whose work reflects a lifelong commitment to Alzheimer's drug discovery and development. Nominees can be a medicinal chemist, pharmacologist, clinical trialist, or neurobiology researcher who embodies a spirit of entrepreneurship and has a history of producing ground-breaking research.
- Be recognized by their peers as a leader and innovator in the field of Alzheimer's drug discovery and development.
- Have published results related to Alzheimer’s and related dementia drug discovery research in significant and peer-reviewed journals and/or as patent applications.
- Be affiliated with a major academic research/medical center, government, industry, and/or non-profit organization(s).